A review of the anticancer effects of sesquiterpene nerolidol on different malignant conditions
Background: Nerolidol (NER) is a sesquiterpene alcohol with various biological and pharmacological activities, especially antitumor effects against different cancer models. The anticancer properties of NER are reportedly mediated by increased reactive oxygen species (ROS) production, apoptosis, ...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Institue of Medicinal Plants, ACECR
2024-03-01
|
| Series: | Journal of Medicinal Plants |
| Subjects: | |
| Online Access: | http://jmp.ir/article-1-3620-en.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Background: Nerolidol (NER) is a sesquiterpene alcohol with various biological and pharmacological activities, especially antitumor effects against different cancer models. The anticancer properties of NER are reportedly mediated by increased reactive oxygen species (ROS) production, apoptosis, and DNA damage. Nevertheless, this compound has low solubility, poor bioavailability, and fast hepatic metabolism, which could be overcome by designing proper nanoformulation scenarios. Objectives: This review focuses on the anticancer effect of NER against multiple cancers to highlight the promising features of NER as an applicable anticancer agent. Methods: A collection of papers based on the ‘cancer’ and ‘NER’ MeSH terms was chosen from NCBI/PubMed, Scopus, and Google Scholar to synthesize the current review. Results: NER was found to act as an adjuvant with contemporary chemotherapy that enhanced the efficacy of chemotherapy drugs on various cancer cells, including osteosarcoma, gastrointestinal, gynecological, breast, skin, blood, liver, and head and neck cancers. Conclusion: NER is an effective antitumor compound against different types of cancers, and its inclusion in the current chemotherapy regimen could improve cancer therapy. Because of low solubility, NER nanoformulation can improve its bioavailability and related cancer treatment. |
|---|---|
| ISSN: | 2717-204X 2717-2058 |